Jan Thorell
Président chez Biolin Medical AB
Profil
Jan Thorell is currently the Chairman at Biolin Medical AB, Director at Medilab AB, and a Professor at both the University of Uppsala and the University of Lund.
In the past, he was the Chairman at Biovator AB and the Director of Research & Development at Phadia AB.
Postes actifs de Jan Thorell
| Sociétés | Poste | Début |
|---|---|---|
Medilab AB
 Medilab AB Medical/Nursing ServicesHealth Services Medilab AB provides healthcare services. The firm offers one-stop-shop for patient samples, departments for clinical chemistry, and microbiology. The company is headquartered in Taby, Sweden. | Directeur/Membre du Conseil | - |
| University of Uppsala | Corporate Officer/Principal | - |
| University of Lund | Corporate Officer/Principal | - |
Biolin Medical AB
 Biolin Medical AB BiotechnologyHealth Technology Part of ME Enterprises Holdings AB, Biolin Medical AB is a Swedish company that manufactures biotechnological and medical products. The company is based in Stockholm, Sweden. | Président | - |
Anciens postes connus de Jan Thorell
| Sociétés | Poste | Fin |
|---|---|---|
Biovator AB
 Biovator AB Miscellaneous Commercial ServicesCommercial Services Biovator AB develops innovative, unique in vitro tests (i.e. in test tubes) which predict the risk for allergic sensitization. Many products, such as pharmaceuticals, cosmetics and food additives may be allergens, causing allergic reactions. For this reason they are tested for allergen city. Up to now such tests have been performed in laboratory animals. Biovator AB is developing two in vitro tests: the Cytokine Profile Assay (CPA) and the Gene Activation Profile Assay (GAPA). CPA will be the first allergen city test of any type, which can predict hypersensitivity reactions of the so called Type I. The Biovator technologies are well in line with EU legislative initiatives such as banning animal testing of cosmetics 2009. | Président | 13/03/2012 |
Phadia AB
 Phadia AB Medical SpecialtiesHealth Technology Phadia AB develops, manufactures and markets blood test systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases. The company was founded in 2004 and is headquartered in Uppdala, Sweden. | Directeur Technique/Scientifique/R&D | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Biolin Medical AB
Biolin Medical AB BiotechnologyHealth Technology Part of ME Enterprises Holdings AB, Biolin Medical AB is a Swedish company that manufactures biotechnological and medical products. The company is based in Stockholm, Sweden. | Health Technology |
Phadia AB
Phadia AB Medical SpecialtiesHealth Technology Phadia AB develops, manufactures and markets blood test systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases. The company was founded in 2004 and is headquartered in Uppdala, Sweden. | Health Technology |
Medilab AB
Medilab AB Medical/Nursing ServicesHealth Services Medilab AB provides healthcare services. The firm offers one-stop-shop for patient samples, departments for clinical chemistry, and microbiology. The company is headquartered in Taby, Sweden. | Health Services |
Biovator AB
Biovator AB Miscellaneous Commercial ServicesCommercial Services Biovator AB develops innovative, unique in vitro tests (i.e. in test tubes) which predict the risk for allergic sensitization. Many products, such as pharmaceuticals, cosmetics and food additives may be allergens, causing allergic reactions. For this reason they are tested for allergen city. Up to now such tests have been performed in laboratory animals. Biovator AB is developing two in vitro tests: the Cytokine Profile Assay (CPA) and the Gene Activation Profile Assay (GAPA). CPA will be the first allergen city test of any type, which can predict hypersensitivity reactions of the so called Type I. The Biovator technologies are well in line with EU legislative initiatives such as banning animal testing of cosmetics 2009. | Commercial Services |
